Our previous studies unraveled a HER2 therapy resistance mechanism in which SorLA supports HER2 protein levels and oncogenicity in breast and bladder cancer in vitro and in vivo [16]. The gene discussed is ERBB2; the disease is urinary bladder carcinoma.